Investors sue Solid Biosciences, say they were duped about Duchenne drug ’s safety

Cambridge-based Solid Biosciences is facing legal claims from investors after disclosing safety issues with its lead drug, a gene therapy treatment for Duchenne muscular dystrophy. Solid (Nasdaq: SLDB) revealed on March 14 that the FDA had halted an early-stage study of the drug after one patient was hospitalized. While Solid said that the patient had recovered, the disclosure sent shares of the newly-public biotech tumbling more than 60 percent. The FDA setback caught the attention of a handful…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news